

PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes
300 Corporate Center Drive, Suite 600, Camp Hill, PA 17011

Wednesday, January 20, 2021 – 12:00 PM – 1:30 PM

Present: Meghan McNelly, PharmD, MHA; FACHE, Dr. Auren Weinberg, Germaine Biksey, RPh, Michelle Bennett, RPh, Debbie Rose (Participant Advisory), Jill Schaeffer, RN, Dr. Mahmood Usman, Dr. Carla Huitt,

Absent:

Guests: Patrick Newsome (Pharmacy), William Baker (Pharmacy), Christina Kauffman (Pharmacy), Amy Williams (Pharmacy), Rhonda Hredzak (Pharmacy), Jason Skaria (Pharmacy Manager), Shalyn Kline (Pharmacy), Jennifer Shepard (Manager Clinical Pharmacy Solutions Medicare), Jay Pagni (Complaints & Grievances), Iris Krug (VP, Compliance, PHW), and George Kimbrow, Jr. (PHW Policy Coordinator)

Call to Order: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:03 PM.

Adjourned: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:33 PM.

Next Meeting: Wednesday, April 21, 2021 – 12:00 PM

Submitted By: William Baker (PHW Pharmacy)

t)Committee Chair: _____

Meghan McNelly, PharmD, MHA; FACHE

Date:

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Meghan McNelly called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:03 PM.	Meeting Called to Order		Meghan McNelly
A. Introductions	No introductions necessary.	Staff attendees noted		Meghan McNelly
B. Announcements	Meghan reminded all that 75% attendance is required for all voting members to remain as active committee members.	No action required or taken.		Meghan McNelly
C. Recording	Meetings will not be recorded from this point forward as Centene, Corporations directive is to not record meetings. Notes will be taken and minutes will be completed and distributed.			Shirley Stahler
D. Explanation of the Review and Approval Process	<ul style="list-style-type: none"> i. Voting and vote totals ii. Tie breaker iii. Pennsylvania’s Review and Approval Process 	No action required or taken.		Meghan McNelly
E. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Meghan McNelly
II. Approval of Meeting Minutes	A vote was taken for the approval of the minutes from Q4_2020. Roll call was taken for approval of minutes.	Adoption of Q4_2020 Meeting Minutes recorded as approved		Meghan McNelly
III. Old Business				
A. Policy Submission Status	There were 80 clinical policies submitted. Out of the 80 policies 76 were approved. There are four outstanding policies and two administrative policies outstanding.	No action required or taken.		William “Bill” Baker/Meghan McNelly

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

New Business				
A. Statewide PDL updates	<p>Statewide PDL changes due to the Department’s annual P&T committee meeting that are effective January 2021.</p> <p>The compliance rate expected is 95% and PHW has a 98% compliance rate. This is monitored monthly and reported to the PBM’s Senior Leadership.</p>			
B. Duchenne Muscular Dystrophy Education	Roll call was taken for approval of the educational material.	The education was Committee approved.		Bill Baker
C. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational		Bill Baker
D. Drug Coverage Criteria	<p>Combined Summary Table:</p> <ol style="list-style-type: none"> 1. HIM Summary Table <ol style="list-style-type: none"> a. 78 policies with clinically significant changes b. 12 new policies c. 146 policies with no clinically significant changes d. 12 policies being retired and/or replaced 2. Medicaid Summary Table <ol style="list-style-type: none"> a. 79 clinical policies <ol style="list-style-type: none"> i. 3 new policies created ii. 39 policies with clinically significant changes iii. 37 policies with no significant changes iv. 9 policies retired (replaced by State-directed PA guidelines) 3. Statewide PDL guidelines 	The policy revisions were Committee approved.		Bill Baker

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

	<p>a. 32 PA guidelines with significant revisions</p> <p>b. 2 new PA guidelines for new market baskets i.e. med classes</p> <p style="padding-left: 40px;">i. Hypoglycemic Treatments</p> <p style="padding-left: 40px;">ii. Sickle Cell Treatments</p> <p>Bill informed the committee that this is the prior authorization guidelines. There were 81 supplemental drugs added to the list. These are non-formulary agents.</p> <p>He took roll call for the approval of the revisions.</p>			
E. Fraud, Waste, and Abuse	<p>Meghan McNelly informed the committee that there was one pharmacy referred to the Office of Inspector General (OIG). The OIG is incorporating our information into a larger investigation that they are working on for the pharmacy.</p> <p>The issues found are for pricing and reimbursement. This is suspected fraud.</p>			Meghan McNelly
F. Complaints and Grievances Review	<p>Jay Pagni presented the pharmacy complaints & grievances for quarter 4 of 2020. There were a total of 48 grievances. Out of those, three were upheld, five were overturned, and 40 were withdrawn. Out of the 48 there were 30 that were for opioids.</p> <p>The withdrawn are handled by doing a pre-grievance review to try to get it resolved.</p> <p>Jason Skaria and Shalyn Kline are reviewing the top 100 requested medications. They are working on creating prior authorization forms that are more specific to help lower the denial rates.</p>			Jay Pagni Jason Skaria - Shalyn Kline

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. § 1137 (b)).

<p>G. PBM Oversight</p>	<p>Jason Skaria presented PBM oversight. He informed the committee that there were 120 requests reviewed in quarter 4. There were 60 approvals and 60 denials reviewed.</p> <p>The high cost approvals were audited for accuracy of clinical decision-making. The denials were audited using elements established in the Quality Improvement Plan (QIP) that was recommended by the state.</p> <p>One Mavyret request was approved for 12 weeks when only eight weeks are medically necessary. The approval duration and override were updated.</p> <p>For the denials, there were two requests that missed the turn around time (TAT) of 24 hours. This has been addressed with increased oversight of TAT on the weekends.</p> <p>There were also two requests denied because the wrong policy was used for the review. The reviewer were coached on the error.</p>			<p>Jason Skaria</p>
<p>H. Drug Utilization Review Updates & Q4 2020 Reporting</p>	<p>Patrick Newsome informed the committee that Jennifer Shepard and he are reviewing the DUR program. The current ACEi/ARBs DUR program will be retired. New programs will be implemented to address the admitting diagnoses of Chest Pain/MI, COPD and shortness of breath.</p> <p>There are four DUR programs that will be potentially implemented for 2021. They are:</p> <ul style="list-style-type: none"> • PCE Measure: Pharmacotherapy Management of COPD Exacerbation • AMR Measure: Asthma Medication Ratio • SPC Measure: Statin therapy for patients with CV Disease (similar to Medicare) • PBH Measure: Persistence of beta-blocker treatment after a heart attack 			<p>Patrick Newsome.</p>

CONFIDENTIAL

Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

	<p>An overview of each 2021 CHC DUR Program was discussed. To see the specifics, please review slide 11. The program aligns with Medicare and HEDIS. There are no concerns.</p> <p>The Drug Utilization Review was completed for Fraud, Waste, and Abuse. Morphine Milligram Equivalent, Multiple opioid prescribers, and the lock in committee were under this review. The finding are listed on slide 12 of the presentation.</p> <p>Inappropriate prescribing was also reviewed. There were no Participants identified for Acetaminophen overutilization. There were six repeat Participants identified as being on antipsychotic with inferred dementia diagnosis.</p> <p>Disease Management was reviewed and it was found that there were 12 Participants identified on long-acting beta-agonist monotherapy. All were previously reviewed. For diabetes without the use of ACE-I or ARB there were 241 faxes sent to the providers.</p>			
<p>I. COVID 19 Response</p>	<p>Continuing point-of-sale edits, hydroxychloroquine limits, and late refill reporting. The late refill reporting was sent to the Service Coordinators.</p> <p>There is information on the website concerning the COVID 19 vaccine. When more information becomes available, it will be added to the site.</p> <p>To find a vaccination sight go to the state website.</p>	<p>No action required or taken.</p>		<p>Meghan McNelly</p>
<p>J. Help Wanted</p>	<ul style="list-style-type: none"> • Seeking P&T member with HIV expertise • Participant member 			

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

K. Open Forum	Nothing discussed.	No action required or taken.		Meghan McNelly
Adjournment	The meeting was adjourned at 12:33 pm	Meeting adjourned		Meghan McNelly

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).